Stockscreener 앱 받기
154.14
1.65%
-2.58
시장 영업 전:
156.35
2.21
+1.43%
전일 마감가:
$156.72
열려 있는:
$154.67
하루 거래량:
1.89M
Relative Volume:
1.09
시가총액:
$294.11B
수익:
$54.66B
순이익/손실:
$13.58B
주가수익비율:
21.97
EPS:
7.0171
순현금흐름:
$16.05B
1주 성능:
+0.67%
1개월 성능:
+5.81%
6개월 성능:
+11.80%
1년 성능:
+25.22%
1일 변동 폭
$153.22
$155.02
1주일 범위
$153.22
$157.89
52주 변동 폭
$112.34
$170.46
노바티스 ADR Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
154.14 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,191.74 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.98 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
251.06 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.37 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Argus | Hold → Buy |
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2026-01-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
3 European Stocks to Carry Investors Through the Back Half of 2026 - Investing.com
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - AD HOC NEWS
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - AD HOC NEWS
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - AD HOC NEWS
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - AD HOC NEWS
NVSNovartis AG ADR Options - Finviz
Novartis strategy highlighted by remibrutinib and Sandoz spin-off, shares steady on SIX - AD HOC NEWS
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - AD HOC NEWS
NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart - ChartMill
Cash flow from operating activities of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG Stock (CH0012005267): Earnings in focus for US investors - AD HOC NEWS
Novartis AG Stock (CH0012005267): Analyst Targets and SMI Role Keep Shares in Focus - AD HOC NEWS
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
Why is Novartis stock rallying today? - Investing.com
Novartis AG Stock (NVS) Moved Down by 3.14% on Jun 1: Key Drivers Unveiled - TradingKey
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.04%
1.73%
자본화:
|
볼륨(24시간):